US Archives - Velocity Clinical Research

Douglas K. Logan, MD, and David Ensz, MD, Author Nature Communications Article

July 3, 2025

Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” The Phase 1/2 Moderna trial results “demonstrate the proof of concept that mRNA-1020 and mRNA-1030 elicit similar HA-specific immune responses to [hemagglutinin] HA-only … Read more

Dr. Rosenstock is the Lead Investigator for Lilly’s ACHIEVE-1 Trial for Oral GLP-1, Orforglipron, Results Published in NEJM

June 23, 2025

Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly’s Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight loss. The results were presented by Dr. Rosenstock at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine. “The … Read more

Launching the 2025 U.S. Clinical Trials Patient Survey

June 16, 2025

At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to listen, learn, and lead—and it’s why we’re excited to share insights … Read more

Velocity’s VISION Reaches More than $12.6 Million in Payments and 10,000 Randomizations

June 11, 2025

VISION has now contributed to more than 10,000 participant randomizations worldwide. Additionally, over $12.6 million in stipends have been paid through the VISION Engage mobile app, which is active in four countries and available in four languages. VISION continues to connect more people to clinical trials, enhance the participant experience, and reduce site burden. Learn … Read more

Velocity Sites Help Deliver Promising Results in NEJM: Once-Weekly Semaglutide Shows Positive Affect on MASH, Liver Fibrosis

May 13, 2025May 9, 2025

Velocity’s sites in Dallas, TX, and Staszów, Poland, enrolled patients in Novo Nordisk’s Phase 3 trial assessing semaglutide’s effect on participants with metabolic dysfunction–associated steatohepatitis (MASH). Trial results were published in a recent New England Journal of Medicine article detailing the GLP-1 receptor agonist’s impact on liver fibrosis. The study found that “in patients with … Read more

Annapolis, MD, Site Recognized as Top U.S. Enroller for Phase 3 Respiratory Trial

February 27, 2025February 18, 2025

Congratulations to our Annapolis, MD, site for being recognized as the top U.S. enroller in a Phase 3 respiratory trial. Established in partnership with Luminis Health, this site also marked Velocity’s entry into oncology in the U.S.

Closing Trust Gaps: The Economic Case for Enhancing Health Equity in Clinical Trials

October 10, 2024October 9, 2024

The pandemic left many notable developments in its wake, not least the increased focus on improving diversity in clinical trials. This issue was thrust into the spotlight during Operation Warp Speed — the accelerated development of a COVID-19 vaccine in the U.S. — and is one Jerome Adams, MD, MPH, who served as U.S. General … Read more

Nick Spittal Comments on Velocity’s Membership With Advarra’s Gene Therapy Ready Site Network

October 3, 2024

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more

Ipsen’s Iqirvo Approved for Use in EU Based on Results Authored by Kris Kowdley, MD

September 24, 2024

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, played an integral role in the clinical research that first gained FDA approval in June 2024, and has now led to the European Union’s approval of Ipsen’s Iqirvo, a groundbreaking therapy for primary biliary cholangitis (PBC), a rare liver condition. As the lead investigator for the Phase 3 … Read more

Velocity Has Supported Research for 12 Products That Have Received FDA Approval in 2024

September 17, 2024

Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024! This year’s groundbreaking approvals include: Ebglyss (lebrikizumab-lbkz) by Eli Lilly, a new treatment for moderate to severe atopic dermatitis (eczema). mRESVIA by Moderna, a vaccine to protect seniors from lower respiratory tract infections caused by RSV. Livdelzi … Read more